Molecular regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Ramipril (brand names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others), a drug used to treat hypertension, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 28/December/2018, 9.36 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing   lncRNA Hand2-AS1 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such a SMAD7/CDK2AP1, BIRC5,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 26/December/2018, 7.55 pm
December 26, 2018
Probiotic-based therapy for glucose homeostasis and TIIDM: Probiotic VSL#3 increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM, via down regulation of its target gene, 28/December/2018, 9.57 pm
December 28, 2018
Show all

Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761)by Prof Tzahor E, D’Uva E, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Ramipril (brand names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others), a drug used to treat hypertension, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene


From the significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs and (iv) a side-effect-free Natural product-based drug.

 


From research findings to Therapeutic opportunity: 

This study suggests, for the first time, Ramipril  may not only protect against cardiovascular diseases, but also aid in promotion of cardiomyocyte (CM) dedifferentiation . Ramipril, by increasing the expression of its target gene, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration.  Thus, pharmacological formulations encompassing Ramipril  or its metabolite Ramiprilat or its analogs, either alone or in combination with other drugs,” may be used to promote cardiac dedifferentiation and regeneration.

Figure1. Mechanistic insights into how Ramipril or its metabolite Ramiprilat may promote cardiac dedifferentiation and regeneration. Ramipril, by increasing the expression of its target genes, it may upregulate the expression of ERRB2/HER2 and aid in promotion of cardiac dedifferentiation and regeneration

Figure 2. Ramipril or its metabolite Ramiprilat may aid in cardiac regeneration through induction of Her2/Erbb2

Given the mechanistic basis of how Ramipril  or its metabolite Ramiprilat may aid in cardiomyocyte survival and regeneration,  medical practitioners and cardiologists may consider conducting a clinical trial or treating myocardial patients with Ramipril and its metabolite Ramiprilat, as they may aid in cardiomyocyte regeneration following myocardial infarction

[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:  Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed (mechanistic insights) information: How does Ramipril  increase the expression of  ERBB2/Her2?

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,   Molecular regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Ramipril (brand names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others), a drug used to treat hypertension, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 28/December/2018, 9.34 pm,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.